Bristol Myers Squibb Co. BMY

What this company does

Bristol-Myers Squibb discovers, develops, licenses, manufactures, markets, distributes and sells medicines. Its marketed chemical products include Eliquis, Revlimid, Pomalyst, Sprycel, Zeposia, Camzyos, Sotyktu, Krazati and Cobenfy. Among the biologics it markets are Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Breyanzi, Opdualag and Abecma. Its products are sold worldwide, principally to wholesalers, distributors and specialty pharmacies and, to a lesser extent, to retailers, hospitals, clinics, government agencies and directly to patients. As of December 31, 2025, the company had approximately 32,500 employees in 43 countries. Its significant biologics, cell therapy and pharmaceutical manufacturing facilities are located in the U.S., Puerto Rico, the Netherlands, Ireland and Switzerland. The business is run as a single segment. Incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887, it took its present name in 1989 as a result of a merger.

Written from the business description in BRISTOL MYERS SQUIBB CO's annual report to the U.S. Securities and Exchange Commission, filed 11 February 2026. Every sentence was checked against that document before publication.